@CMA_Docs Pts with #mecfs aka chronic fatigue syndrome improved with 2 infusions of Rituximab.Pts need access 2 it http://t.co/DLnqRYYN
@BioPressRelease Pts with #MECFS helped by cancer drug Rituximab http://t.co/DLnqRYYN
@bbchealth Patients with #MECFs helped by cancer drug Rituximab http://t.co/DLnqRYYN It is not in our heads
#rheum Patients with #mecfs (aka chronic fatigue syndrome) helped by Rituximab. Could you please help us? http://t.co/DLnqRYYN
@healthcouncilca http://t.co/DLnqRYYN Patients with #MECFS improved with Rituximab. We need larger trials for canadian pts. Please help!
@HealthCanada http://t.co/DLnqRYYN Patients wiht #mecfs helped by Rituximab- a norwegian study. Canadian patients need pilot study ASAP.
Rituximab shownto help patient with #MECFS... But is Roche interested to help them? Roche, do the right thing. http://t.co/DLnqRYYN
@maasbrenn @MariasMetode Prøv her: http://t.co/IQWMP6FJ
RT @egilfors: Fukuda-kriterier og CFS betegnelse ved strålende forskning: http://t.co/R30KYdHY
@maasbrenn Lenke først i bloggposten til fulltekst i PLoS ONE: http://t.co/Fk4EJAz7 @mariasmetode
@maasbrenn Ja, Rituximab ved ME-artikkelen er publisert i PLOSOne og er fritt tilgjengelig: http://t.co/4SMsvYce
@maasbrenn her: http://t.co/yBu0valu @MariasMetode
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in #CFS. | PLoS ONE http://t.co/6xMrqVH2
Link to the #Rituximab paper on myalgic encephalomyelitis / chronic fatigue disorder in PLosOne: http://t.co/648Qad2k #ME #CFS
Conclusion: "The delayed responses starting from 2–7 months after Rituximab treatment, in spite of rapid B-cell... http://t.co/W1ck40Jy
"Sensational" results in Norwegian breakthrough DBPC study on Rituxan in #mecfs http://t.co/20wMjZ8c PLoS One: http://t.co/TdqmyuGW #cfs
Fukuda-kriterier og CFS betegnelse ved strålende forskning: http://t.co/R30KYdHY
RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/PIqZKkyR #mecfs #cfs #xmrv #rituximab
Et mulig håp for ME-pasienter? Ny studie utført av Haukeland universitetssykehus tyder på det: http://t.co/lr4fxVLj
RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/PIqZKkyR #mecfs #cfs #xmrv #rituximab
RT @kaazoom: Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in #MECFS. A Placebo-Controlled Study http://t.co/kBsr629d
RT @DeBortgjemte: Here's the study on Rituximab/Rituxan in ME/CFS that shows major improvement in 67 % of patients http://t.co/0b5Fuko8 #ME #CFS @PLoSONE
RT @Vansteenwinckel: RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/gc4S6LrT #mecfs #cfs #xmrv #rituximab #mecfs
RT @DeBortgjemte: Here's the study on Rituximab/Rituxan in ME/CFS that shows major improvement in 67 % of patients http://t.co/0b5Fuko8 #ME #CFS @PLoSONE
RT @Vansteenwinckel: RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/gc4S6LrT #mecfs #cfs #xmrv #rituximab #mecfs
RT @Vansteenwinckel: RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/gc4S6LrT #mecfs #cfs #xmrv #rituximab #mecfs
RT @DeBortgjemte: Here's the study on Rituximab/Rituxan in ME/CFS that shows major improvement in 67 % of patients http://t.co/0b5Fuko8 #ME #CFS @PLoSONE
RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/PIqZKkyR #mecfs #cfs #xmrv #rituximab
RT @PlzSolveCFS: EXCITING NEWS: PLoS ONE reports results of Rituxin trial in 30 CFS patients. 67% rec'd durable benefit. http://t.co/DBM27O9w More to come!
Promising news: Results of Rituxin trial in 30 CFS patients. 67% rec'd durable benefit. http://t.co/yIwDZwjL @PlzSolveCFS
@doctorchristian Here's the full CFS paper http://t.co/qebi9Dvw
RT @DeBortgjemte: Here's the study on Rituximab/Rituxan in ME/CFS that shows major improvement in 67 % of patients http://t.co/0b5Fuko8 #ME #CFS @PLoSONE
Here's the study on Rituximab/Rituxan in ME/CFS that shows major improvement in 67 % of patients http://t.co/0b5Fuko8 #ME #CFS @PLoSONE
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in #MECFS. A Placebo-Controlled Study http://t.co/kBsr629d
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double... http://t.co/DzPSKvfh
Breakthru Norway research: #PLoS: Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chro... http://t.co/72anHHpX
Full report on M.E/cancer drug! http://t.co/WxREN7Yh
RT @Stjernesand: Her er studien til kreftlegene ved Haukeland, publisert nå i kveld. http://t.co/HW1eDUK3 Dette gir håp for #ME-pasienter verden over. #helse
RT @DeBortgjemte: Rituximab/Rituxan-study in ME/CFS out in PLoS ONE. 67 % of patients major improvements in all symptoms http://t.co/0b5Fuko8
RT @DeBortgjemte: Rituximab/Rituxan-study in ME/CFS out in PLoS ONE. 67 % of patients major improvements in all symptoms http://t.co/0b5Fuko8
RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/PIqZKkyR #mecfs #cfs #xmrv #rituximab
RT @MEAssociation: Link to the full Rituximab paper in PLosOne: http://t.co/PIqZKkyR #mecfs #cfs #xmrv #rituximab
Rituximab/Rituxan-study in ME/CFS out in PLoS ONE. 67 % of patients major improvements in all symptoms http://t.co/0b5Fuko8
RT @Stjernesand: Her er studien til kreftlegene ved Haukeland, publisert nå i kveld. http://t.co/HW1eDUK3 Dette gir håp for #ME-pasienter verden over. #helse
Link to the full Rituximab paper in PLosOne: http://t.co/PIqZKkyR #mecfs #cfs #xmrv #rituximab
EXCITING NEWS: PLoS ONE reports results of Rituxin trial in 30 CFS patients. 67% rec'd durable benefit. http://t.co/DBM27O9w More to come!
RT @StineCamilla: Her er studien om behandling av #ME som omtales som et medisinsk gjennombrudd på TV2-nyhetene nå. http://t.co/LHweP5KP #plosone
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. http://t.co/mLY3vFdW #CFS #ME
@JarlePetterson Da har PLoS One publisert: http://t.co/qb6zS382
Her er studien om behandling av #ME som omtales som et medisinsk gjennombrudd på TV2-nyhetene nå. http://t.co/LHweP5KP #plosone
Fantastisk om ME på TV2 nå! Studien er publisert: http://t.co/7TesRt1Z
RT @catwesterby: Studie om #ME og #Rituximab publisert nå: http://t.co/DoDKElIQ
RT @catwesterby: Studie om #ME og #Rituximab publisert nå: http://t.co/DoDKElIQ
Studie om #ME og #Rituximab publisert nå: http://t.co/DoDKElIQ